First, much attention has to be paid to reaching the equilibrium, which is slow in case of many chelators including NTA
Malaspina, W
All patients receive a custom diet and exercise plan included in their program
History of pancreatitis or gallbladder disease: Use is discouraged because these medications can increase risk
In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity
Shared decision-making is crucial, incorporating discussion of treatment goals, potential risks, expected benefits, cost considerations, and alternative options